OS Therapies

About OS Therapies

OS Therapies (OST) is a clinical-stage cancer immunotherapy company focused on developing innovative treatments to activate the immune system against cancers expressing HER2, such as Osteosarcoma, Breast Cancer, Colorectal Cancer, and other solid tumors. Their mission is to revolutionize cancer treatment and address urgent needs for new therapies, starting with Osteosarcoma, and expanding to other cancers like Breast, Esophageal, Lung, Ovarian, and Pancreatic cancers.

Products & Services

OST-HER2 Immunotherapy:A novel cancer immunotherapy targeting HER2-expressing cancers to activate killer T cells against tumor antigens, primarily for Osteosarcoma and other solid tumors.

OST-tADC Tunable Antibody Drug Conjugate:A silicone linker platform for next-generation cancer treatments, enhancing the therapeutic approach to various cancers.

Specialties

Cancer Immunotherapy HER2 Targeted Therapies Osteosarcoma Treatment Solid Tumor Treatments Antibody Drug Conjugates

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Inducement T: - FT: Warrant Inducement	A: 7530000 MR: - FA: $7.53M FAN: 7530000	D: 2026-01-12 FD: 2026-01-12	1 investors
2	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3700000 MR: - FA: $3.7 million FAN: 3700000	D: 2025-09-02 FD: 2025-09-02	-
3	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4200000 MR: - FA: $4.2 million FAN: 4200000	D: 2025-08-25 FD: 2025-08-25	1 investors
4	RT: Warrant Exercise and Exchange Offer T: - FT: Warrant Exercise and Exchange Offer	A: 4200000 MR: - FA: 4.2 million FAN: 4200000	D: 2025-07-14 FD: 2025-07-14	-
5	RT: Private Placement T: - FT: Private Placement	A: 6000000 MR: - FA: approximately $6 million FAN: 6000000	D: 2024-12-31 FD: 2024-12-31	1 investors
6	RT: Private Placement T: - FT: Private Placement	A: 6000000 MR: - FA: $6 million FAN: 6000000	D: 2024-12-24 FD: 2024-12-24	-
7	RT: IPO T: - FT: IPO	A: 6400000 MR: - FA: $6.4 million FAN: 6400000	D: 2024-07-31 FD: 2024-07-31	1 investors

Warrant Inducement Latest

2026-01-12

$7.5M

1 investor (Pro only)

Warrant Exercise 2025-09-02

$3.7M

Warrant Exercise 2025-08-25

$4.2M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paul Romness

Chair, Chief Executive Officer, President

R

Robert Petit

Chief Medical & Scientific Officer, Founding Scientist (OST-HER2)

G

Gerald Commisiong

Chief Business Officer

J

Jutta Wanner

Advisor, Founding Scientist (OST-tADC)

J

Jack Doll

Chief of Staff

C

Chris Acevedo

Chief Financial Officer

View 26 more team members with Pro

Unlock Full Team Directory

Recent News

OS Therapies Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised